Hanif Muhammad, Meier Samuel M, Adhireksan Zenita, Henke Helena, Martic Sanela, Movassaghi Sanam, Labib Mahmoud, Kandioller Wolfgang, Jamieson Stephen M F, Hejl Michaela, Jakupec Michael A, Kraatz Heinz-Bernhard, Davey Curt A, Keppler Bernhard K, Hartinger Christian G
School of Chemical Sciences, University of Auckland, Private Bag 92019, Auckland, 1142, New Zealand.
Institute of Inorganic Chemistry, Faculty of Chemistry, University of Vienna, Waehringer Strasse 42, 1090, Vienna, Austria.
Chempluschem. 2017 Jun;82(6):841-847. doi: 10.1002/cplu.201700050. Epub 2017 Apr 5.
Hydroxypyr(id)ones constitute an emerging platform for the design of drug molecules, owing to their favorable biocompatibility and toxicity profiles. Herein, [Ru (η -p-cymene)] complexes with 3-hydroxy-2-pyridinone functionalized with morpholine and thiomorpholine, as a means often used in medicinal chemistry to alter the physicochemical properties of drug compounds, are reported. The compounds underwent hydrolysis of the Ru-Cl bond and the aqua species were stable for up to 48 h in aqueous solution, as observed by H NMR spectroscopy and ESI-MS. The compounds formed adducts with amino acids and proteins through cleavage of the pyridinone ligand. Binding experiments to the nucleosome core particle by means of X-ray crystallography revealed similar reactivity and exclusive binding to histidine moieties of the histone proteins. Preliminary cyclin-dependent kinase 2 (CDK2)/cyclin A kinase inhibitory studies revealed promising activity similar to that of structurally related organometallic compounds.
由于具有良好的生物相容性和毒性特征,羟基吡啶酮构成了一个新兴的药物分子设计平台。在此,报道了[Ru(η -对异丙基苯)]与用吗啉和硫代吗啉官能化的3-羟基-2-吡啶酮形成的配合物,这是药物化学中常用于改变药物化合物物理化学性质的一种方法。通过核磁共振氢谱和电喷雾质谱观察到,这些化合物发生了Ru-Cl键的水解,并且水合物种在水溶液中稳定长达48小时。这些化合物通过吡啶酮配体的裂解与氨基酸和蛋白质形成加合物。通过X射线晶体学对核小体核心颗粒进行的结合实验表明,其具有相似的反应活性,并与组蛋白的组氨酸部分特异性结合。初步的细胞周期蛋白依赖性激酶2(CDK2)/细胞周期蛋白A激酶抑制研究显示出与结构相关的有机金属化合物相似的有前景的活性。